FDA Ending Enforcement Discretion for Tirzepatide Copies After Court Denies Preliminary Injunction
- March 14, 2025
The Food and Drug Administration (FDA) has ended enforcement discretion for state-licensed pharmacy compounding of Eli Lilly & Co.’s drug tirzepatide after a federal court in Texas refused to issue a preliminary injunction enjoining the agency’s decision to remove the obesity and diabetes treatment from its shortages list.
ARTICLE TAGS
You must be logged in to access this content.